66,
My view is simple. DARRT 2, IONIC, CEP 2, LuPIN will of course inform us just how good Veyonda is. That hasn't changed - no bad news there.
The delays in recruitment - as revealed in the latest quarterly report - will act as a testament to the ability of the Noxopharm Board to move things along.
Both on trial at the moment. Gotta have the pair in synch.
I see the Board doing their job, so that Veyonda can do its.
58
Ann: March 2022 Quarterly Activities Report and Appendix 4C, page-40
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.010(9.52%) |
Mkt cap ! $33.60M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 14.0¢ | 11.0¢ | $559.0K | 4.481M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6612 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 99714 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |